Deutsche Bank makes perfect sense to handle the offering since Germany will be one of the first EU countries Qsiva will be available. Funny, make sure you read the statement closely.
Thanks for the update merry. Well done, much appreciated. Vivus management has their hands full over the next 2 months. This is getting too interesting!!!
todzun, van has lost it. Either he's trying to drive the price lower because he sold low and is trying to get back in low, or he has gone short. Van, if you're reading this, good luck to you with your endeavors, but shorting Vivus at this stage or trying to get back in.........is a losing effort. I'll be waving in your direction (East) from the beach in Bora Bora after Vivus sells the company outright.
Hi merry. Sometimes people just don't know how to read text. That's why person to person works soooo much better. Anyway, how did the call go? Can you share some highlights with us? And how is the weight loss going for you?
The little "Cross Dresser", Thomas Wei from Jefferies. And as huge_run_up stated, the little cross dresser was unable to make it to the qtrly call this time around. What a small little individual.
I hate it when I'm right. Astrazeneca will be the BP. Maybe in excess of the $15.2B they paid for Medimmune. Just a matter of time.
Anyone think this can go viral across other CBS affiliates or other networks? Seems like a big fat news story you wouldn't want to hide in a bushel basket.
mooky......not matter how bad we all want DTC advertising and how important it is to creating awareness of Q, it won't start until late July into August at the earliest. We knew this last july 27th when Q was approved by the FDA. Nothing has changed between then and now. It is still being played out exactly how Vivus management said it would. It's all a differnet story once Q is in Bricks and mortar pharmacies and the DTC advertising is lighting up the airwaves, billboards, magazines and banner/pop ups on the world wide web. Also, remember all long investors in this stock, it wasn't Vivus management who drove the price up to $31 at day of approval. It was the professionals and open market. And like any smart individual would do, management sold some shares, knowing they had more and can grant more in the future. Any smart investor should have sold at the top and bought on the way down where it now belongs until there is concrete data on sales of their therapies or the company is bought out right by a BP. There's nothing wrong with a $1.3B market cap at this stage of their development........it's just that the $3.1B was too high of a market cap for the stage it was at at the time. I only wish I would have sold more than half my shares like I did at $29.50. I've still made a bundle over the years but nothing like what we all will be making in the not so distant future.